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Abstract 31 
Objective: Phenotypic changes of chondrocytes toward hypertrophy might be fundamental in the 32 
pathogenesis of OA, of which type X collagen (Col10) is a well-known marker. The purpose was to develop a 33 
specific immunoassay for blood quantification of a newly identified neo-epitope of type X collagen to assess 34 
its diagnostic value for radiographic knee osteoarthritis (OA).  35 
Methods:  A neo-epitope of Col10 was identified in urine samples from OA patients. A monoclonal antibody 36 
against the neo-epitope was produced in Balb/C mice. The enzyme responsible for the cleavage was 37 
identified. Immunohistochemical detection of this neo-epitope was performed on human OA cartilage. An 38 
immunoassay (Col10neo) was developed and quantified in two clinical studies: the C4Pain-003 and the NYU 39 
OA progression study. ROC curve analysis was carried out to evaluate the discriminative power of Col10neo 40 
between OA and RA. 41 
Results: A neo-epitope specific mAb was produced. The Cathepsin K-generated neo-epitope was localized 42 
to the pericellular matrix of chondrocytes, while its presence was extended and more prominent in 43 
superficial fibrillation in the cartilage with advanced degradation. In the C4Pain study, a higher level of 44 
Col10neo was seen in subjects with greater KL grade. The group of the highest tertile of Col10neo included 45 
more subjects with KL3-4. In the NYU study, Col10neo was statistically higher in OA than control or RA. ROC 46 
curve analysis revealed area under the curve was 0.88 (95% CI 0.81-0.94).  47 
Conclusion: Our findings indicate that Col10neo linked to hypertrophic chondrocytes could be used as a 48 
diagnostic biochemical marker for knee OA. 49 
 50 
Key words: chondrocyte hypertrophy, assay, biomarker, type X collagen, Osteoarthritis, Cartilage 51 
 52 
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Introduction 1 
Osteoarthritis (OA) is the most common joint disease, which is characterized by cartilage damage and 2 
impaired joint function
1
. It can implicate synovial joints, but knees, hands, hips, and spine are usually 3 
affected by this disease
2
. A range of risk factors, such as aging, gender, obesity, early trauma, and heredity 4 
are associated with osteoarthritis of the knee
3
.  5 
Although substantial progress has been made to understand the mechanisms leading to degradation of the 6 
cartilage matrix in OA, the exact pathogenesis of OA still needs to be elucidated. Supported by emerging 7 
evidence hypertrophy of chondrocytes, the only cells present in cartilage is a key event in the development 8 
of OA
4, 5,6,7,8
.   The time course of expression of type X collagen, a specific marker of hypertrophic 9 
chondrocytes, and MMP13 has shown to be significantly induced during OA progression in a surgically 10 
induced joint instability OA model
9,5
. In sections of human osteoarthritic cartilage, type X collagen was 11 
found around hypertrophic chondrocyte clusters in the deep zone close to tidemark
10
. Also, Eerola et al. 12 
demonstrated that intense immunostaining of type X collagen was observed specifically at sites of 13 
osteophyte formation and surface fibrillation
11
. Furthermore, the mineralization process has been shown in 14 
OA cartilage indicating that articular chondrocytes from OA joints develop terminal differentiation similar 15 
to those in the growth plate during endochondral ossification
12
. Conclusively, chondrocyte hypertrophy is 16 
associated with OA. 17 
Cartilage degradation is a common feature for rheumatoid arthritis (RA), a systemic autoimmune disorder 18 
as well.  The degradation of cartilage matrix in both OA and RA is mediated by the overexpression of 19 
enzymes, mostly of MMPs and ADAMTSs
13,14
. However, the driving force behind the development of these 20 
two disorders is different as summarized by Pap et al. in a review
15
. In OA, cartilage loss occurs as part of a 21 
phenotypic shifting of chondrocytes, while in RA, cartilage damage is considered a result of activated 22 
synovial fibroblast-like synoviocytes (FLS) and monocytes.  23 
In the current study, we have discovered a neoepitope of type X collagen, 
479
GIATKG, in the urine samples 24 
of osteoarthritis patients. The Cathepsin K-mediated neo-epitope is in the region near the carboxyl-25 
terminal end of the triple helix. We produced a neo-epitope specific monoclonal antibody and identified 26 
the productive enzyme responsible for the generation of the neo-epitope in vitro. We performed 27 
immunostaining of osteoarthritis cartilage to show the distribution of the neo-epitope. We developed an 28 
enzyme-linked immunosorbent assay (ELISA). In two clinical studies, blood levels of type X collagen 29 
degradation biomarker-Col10neo are associated with Kellgren-Lawrence (KL) grade radiographic severity. 30 
Most importantly, Col10neo biomarker could distinguish between OA and RA and suggest the potential 31 
diagnostic value of this biomarker for knee OA. 32 
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Methods 33 
Materials  34 
Unless otherwise stated, all materials used for experiments were ordered from Sigma-Aldrich (Copenhagen, 35 
Denmark) or VWR (Rodovre, Denmark). The synthetic peptides were purchased from GenScript (USA).  36 
 37 
Selection of the sequence for immunization 38 
Ten urine samples of peri/postmenopausal women with knee pain undergoing arthroscopy were analyzed 39 
by GC/MS and the Mascot database was searched for type X collagen neo-epitopes. Seventeen peptide 40 
sequences were found to be unique to human type X collagen. Two sequences carrying the same free c-41 
terminus located at amino acid (aa) position 478’ (Accession No.: Q03692; UniProt) were discovered in the  42 
urine from OA patients, indicating the cleavage occurring between the bond of A
478
-
479
G. The first 10 aa, 43 
479
GIATKGLNGP
488
, of the free N-terminal end generated by this cleavage was selected for immunization. 44 
Further, a sequence alignment with different species was conducted using the Basic Local Alignment Search 45 
Tool (BLAST). 46 
 47 
Monoclonal antibody (mAb) production 48 
Six female Balb/C mice of 6-7 weeks of age were used for monoclonal antibody production and the 49 
experiment was approved by the Danish Animal experimentation Council. Six mice were housed in the 50 
same cage (the standard type III cage, Scanbur) in a ventilated closet and provided with free access to tap 51 
water and food. The 12-hour light/dark cycle was used in the animal facility with a temperature of 18-22
0
C. 52 
Wood shavings were used for bedding. The mice were immunized subcutaneously with emulsified 53 
GIATKGLNGP-GGC-KLH with Sigma Adjuvant System®(S6322, Sigma-Aldrich). 100µg of emulsified KLH-54 
conjugate with adjuvant was repeatedly injected into mouse every 3
rd
 week until stable titer levels were 55 
obtained. The behavioral assessments were carried out throughout the study. Red bumps after injection 56 
were expected and observed. There was no skin infection observed at the sites of injection. 57 
 The mice with the highest antibody titer and best reactivity towards the specific peptide, GIATKGLNGP, 58 
were chosen for fusion and boosted intraperitoneally (i.p.) with 100 µg of 100 µL KLH-conjugate three days 59 
before fusion. The isolated splenocytes were  fused with murine myeloma cells, SP2/0-Ag14 (ATCC®CRL-60 
1581™).  Hybridoma cells were selected by using HAT (hypoxanthine-aminopterin-thymidine) medium. 61 
Supernatants were screened against GIATKGLNGP-k (Biotin)    Limiting dilution method was used to get 62 
monoclonal antibody and isotype was tested with kit (5300-05, Southern Biotech). Hi Trap Protein G 63 
column (17-0404-01, GE healthcare) was used for purification. 64 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3 
 
 65 
479GIATKG specific immuno-assay (Col10neo) 66 
A purified monoclonal antibody was first tested for specificity against three synthetic peptides 1) specific 67 
peptide (GIATKGLNGP), 2) elongation of the specific peptide (AGIATKGLNGP), 3) truncation of the specific 68 
peptide (IATKGLNGP), and two truncated recombinant type X collagen proteins [Col10(AA 479-680) and 69 
Col10 (AA 450-680)] respectively in a competitive immunoassay. The optimized competitive immunoassay 70 
protocol: a 96-well streptavidin pre-coated microplate was coated with 1ng/mlGIATKGLNGP-k(Biotin) 71 
dissolved in 50mM PBS-BTB for 30 min at 20
0
C.  Then, the plate was washed five times with wash buffer (20 72 
mM Tris, 50 mM NaCl, pH 7.2). 20µL of  standards,controls or samples were added to appropriate wells, 73 
followed by 100µL of 23ng/ml 2F4in 50mM PBS-BTB buffercontaining 5% Liquid II (Roche Diagnostics, 74 
Germany), and incubated overnight (20±1 hr) at 4
0
C. After five times wash, 100µL of secondary antibody 75 
(115-035-003, Jackson ImmunoResearch)  was added and incubated for 1hr at 20
0
C.   The plate was washed 76 
five times again. Finally, 100µL 3,3’,5,5’-tetramethylbenzidine (TMB) was added and incubated for 15 min 77 
at 20
0
C in the dark. The colorimetric reaction was stopped by adding 100µL stopping solution (1% H2SO4) 78 
and measured at 450nm with 650nm as the reference.  79 
The inter- and intra-plate variation were determined by ten independent runs of the quality control panel 80 
in duplicate. The lower limit of detection (LLOD) was calculated as  3SD    of the mean value of 21 zero 81 
standards.  The optimal range for quantitative measurements is defined as the boundary between the 82 
lower limit of quantification (LLOQ) and the upper limit of quantification (ULOQ). Linearity of the assay was 83 
evaluated.  84 
 85 
In vitro cleavage of human cartilage and western blot 86 
Articular cartilage biopsies from OA patients   who   underwent knee replacement surgery were obtained 87 
from Gentofte Hospital (Gentofte, Denmark).  The collection and retrieval of the biospecimens  complied 88 
with international ethical guidelines for handling human samples and patient information. All participants 89 
signed informed consent, and the study was approved by Danish authority.  To identify the enzymes 90 
responsible for the cleavage of the A
478
-
479
G bond in Col10, a knee cartilage pool of 10 OA patients 91 
undergoing knee replacement surgery  was cleaved by numerous proteases including matrix 92 
metalloproteases-2, -9, -13 Cathepsins K, B, S, and A disintegrin and metalloprotease domains with 93 
thrombospondins motifs-4, -5. Briefly, pulverized cartilage sample (30mg) was incubated with 1µg each 94 
enzyme in a 0.5ml Eppendorf with 250µL digestion buffer as previously reported
16
. The digestion was 95 
carried out for 24h in replicates.  The reaction was quenched by adding EDTA  (5mM)  or E64 (5mM). 96 
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Cleaved products from Cathepsin K and control were suspended in the gel-loading buffer and 97 
electrophoresed on 4-12%  Tris-Glycine gradient gel and transferred to nitrocellulose by iBlot®. The blots 98 
were blocked with 5% BSA in TBST, washed and probed with antibodies of 2F4 or 11G8 (antibody against 99 
the carboxyl end of type X collagen developed in our previous study)
17
, in the absence or presence of 100 
blocking peptides in parallel. 101 
 102 
Immunohistochemistry (IHC) 103 
Cartilage with bone specimens for IHC study was performed in collaboration with Frederikshavn Hospital 104 
(Denmark) approved by Danish authority (N-20110031). All participants signed informed consent. The 105 
specimens isolated from OA patients who underwent knee replacement surgery were fixed and decalcified, 106 
and then embedded in paraffin. Cartilage sections (5µm) were deparaffinized and hydrated, followed by 107 
antigen retrieval using Pronase  E  (10165921001, Roche) at  37
0
C for 10  min. The sections were treated 108 
with 0.5% casein in Tris Buffered Saline (TBS) for 30min at room temperature to block unspecific binding. 109 
Immunostaining was performed using antibody 2F4 or 11G8. Non-sense mouse IgG was used as a negative 110 
control (X0931, Dako, Denmark).  Immunoreactivity was visualized with peroxidase-labeled anti-Mouse and 111 
diaminobenzidine (DAB, Dako, Denmark). Counterstaining was with Mayer’s hematoxylin. The micrographs 112 
were taken using an Olympus microscope BX60 equipped with an Olympus C5050 digital camera.  113 
 114 
Study participants 115 
Plasma samples were retrieved from two cohorts, the C4Pain study approved by the local ethics committee 116 
(N-20100094)
18
 and the NYU OA progression study by the institutional review board (IRB) of NYU School of 117 
Medicine 
19,20
. All participants provided informed consent before enrollment.  118 
Briefly, the C4Pain is a cross-sectional study. It comprised 281 individuals with radiographic KL grade 0-4. 119 
Since most patients had bilateral knee OA, the knee with the maximal pain intensity for the last 24 hours 120 
was selected as the signal knee. Sufficient samples were available only from 253 enrollees and categorized 121 
into four groups based on the KL grade since the radiographic features instead of pain were the primary 122 
focus of the current study. 123 
The NYU study comprised 21 non-OA healthy controls (KL≤1 and no pain in either knee), 146 symptomatic 124 
knee OA patients and 36 RA patients at baseline. These 146 OA patients were further followed up for 24 125 
months. The inclusion and exclusion criteria, radiographic assessments were taken at baseline and 24 126 
months and plasma were collected at baseline as described previously
19,20
. Plasma samples were available 127 
from 20 non-OA healthy controls, 142 OA subjects and 34 RA subjects at baseline. In the present study, we 128 
only investigated the level of Col10neo in different groups at baseline.  129 
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 130 
Statistics 131 
Data were analyzed using GraphPad Prism 6 or MedCalc 16.8. For normality check, a Shapiro-Wilk test for 132 
all variables of interest was performed. Between-group comparison for age, BMI and VAS score, the one-133 
way ANOVA with post-hoc Tukey-Kramer test was used. Plasma Col10neo data were logarithmic 134 
transformed in all analyses. The ROC curve analysis was performed. The area under the curve was used to 135 
determine how well Col10neo can distinguish between OA and RA groups. A P value<0.05 was considered 136 
statistically significant. One asterisk (*) if p<0.05; two (**) if p<0.01; three (***) if p<0.001 and four (****) if 137 
p<0.0001. 138 
 139 
 140 
Results 141 
Sequence alignment of the selected peptide across species   142 
Two fragments sharing the identical C-terminal end,  
463
PGSKGDPGSPGPPGPA
478
  and  143 
465
SKGDPGSPGPPGPA
478
 were identified by mass spectrometry in the urine samples of OA patients (Fig. 1A), 144 
indicating the presence of a cleavage site existing between A
478
-
479
G. A 10aa length peptide from the free N-145 
terminus generated by the cleavage, 
479
GIATKGLNGP, has been chosen for immunization.  The blast shows 146 
the sequence is unique to human type X collagen. Sequence similarity across species shows 100% identity 147 
between human and mouse,  while a mismatched aa contained in rat or bovine compared to human 148 
sequence.  149 
 150 
Technical performance of the Col10neo assay 151 
A monoclonal antibody 2F4 (isotype: IgG2b, κ) targeting the neo-epitope, 
479
GIATKG, was produced from a 152 
hybridoma and purified by HiTrap Protein G affinity column. To test the specificity, the reactivity of 2F4 153 
toward a biotinylated synthetic peptide, GIATKGLNGP-k(Biotin), completely displaced by adding of 500nM 154 
selective peptide or equivalent amount of truncated recombinant type X collagen with free 
479
Glycine (AA 155 
479-680). In contrast, a slight or no displacement of binding between the immobilized specific peptide and 156 
2F4 was observed either with elongation/truncation of the specific peptide or cleavage-spanning 157 
recombinant type X collagen (AA 450-680) at the same concentration (Fig. 1B). This indicated that 2F4 was 158 
specific to the neo-epitope instead of intact type X collagen. 159 
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. The technical performance of this assay is summarized as follows: IC50 of 41.9ng/ml, inter-, intra CV% of 4 160 
and 9.7%,. The detection range was 15-426ng/mL. 8-64 fold for EDTA-plasma and 4-32 fold for serum 161 
samples are of high dilution linearity.  (See supplementary table S1). 162 
  163 
Cathepsin K-derived 479GIATKG 164 
To investigate the responsible enzyme for cleaving Col10 A
478
-
479
G bond, various proteases at similar 165 
concentration and incubation time were incubated with human cartilage and evaluated their relative 166 
efficiency to generate the neo-epitope of 
479
GIATKGLNGP. We did not identify release of Col10neo in all 167 
tested MMPs or ADAMTSs compared to untreated control. However, among the proteases, Cathepsin K  168 
yielded substantial amount of Col10neo release (Fig. 2A). In an immunoblot, major band detected by 2F4 169 
mAb in Cathepsin K degraded cartilage was ~50kDa representing the trimeric form of the NC1 domain. In a 170 
completion Western blot, GIATKGLNGP peptide blocked 2F4 mAb recognition of fragment carrying the neo-171 
epitope of  
479
GIATKGLNGP. Furthermore,  mAb 11G8 detected  a 18kDa  protein band was which is most 172 
likely the monomeric NC1 domain of type X collagen (Fig. 2B). 173 
 174 
Immunolocalization of 479GIATKG in cartilage 175 
To further define the distribution of 
479
GIATKG, serial sections of articular cartilage from 3 TKR (total knee 176 
replacement) patients were stained with mAb 2F4 (Col10neo) and 11G8 (anti-C terminus of type X collagen) 177 
and non-sense mouse IgG of cartilage.  A representative histological images of damaged and undamaged 178 
cartilage biopsies 1) the normal-arranged chondrocytes, smooth surface and mild degradation of superficial 179 
zone proteoglycan (Fig.  3A), 2) loss of smooth surface and moderate loss of proteoglycan (according to 180 
Mankin grading system
21
) (Fig. 3B) and 3) chondrocyte clusters, fibrillated surface, cleft and severe 181 
reduction in safranin O/Fast green (Fig. 3C) were used for general assessment of degree of loss of 182 
proteoglycan, chondrocyte morphology, and Col10neo expression. In mild and moderate degradation of 183 
cartilage, GIATKG neo-epitope was localized to the peri-cellular matrix of chondrocytes, while in severe OA 184 
its presence was extended to the territorial matrix of chondrocyte clusters and more prominent in 185 
superficial fibrillation (Fig. 3D-F). The similar staining pattern was observed with C-terminus 11G8 mAb (Fig. 186 
3G-I)..  We did not observe any staining with non-sense mouse IgG (Fig. 3J-L). 187 
 188 
Association between KL grade and plasma Col10neo levels in the C4Pain study 189 
The demographic characteristics of these four groups based on radiogrpahic KL score are summarized in 190 
table 1. Because the mean age of the participants was >60 years, few with a KL 0 and those with a KL of 1 191 
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were classified into the same group. 57% of the subjects involved in this study were with a KL of 2 and 192 
assigned to group 2. There was no significant difference in gender distribution within each group. The mean 193 
age of KL 4 group was significantly higher than KL 0-1 group (p< 0.005). There was a clear, but not 194 
significant trend of increased BMI with increased radiographic grades.. There was a relationship between 195 
the VAS score and K/L grade, but did not reach statistical significance. 196 
The mean ± 95CI% concentrations of Col10neo for in each KL groups:  KL 0-1 2.6 [2.316-2.884] μg/mL, KL2 197 
3.288[2.885-3.691] µg/mL, KL3 3.435[2.729-4.141] µg/mL and KL4 3.517[2.599-4.435] µg/mL, respectively. 198 
Although increased Col10neo levels associated with a higher KL grade, but it was not statistically significant 199 
(Fig. 4A). However, when subjects were divided into tertiles based on Col10neo levels, we found that the 200 
number of subjects with a KL 3-4 was greatest in the highest tertile of the Col10neo group (Fig. 4B). 201 
 202 
Plasma Col10neo levels in the NYU study 203 
The result from the C4Pain study encouraged us to investigate the potential use of Col10neo as a diagnostic 204 
biomarker in another independent cohort of control and OA subjects. We utilized NYU Progression study 205 
which consists of non-OA healthy control, OA, and RA. In this cohort, percentage of females was higher in 206 
OA and RA groups than in the healthy control group. The mean age was significantly different in control and 207 
OA groups (P˂0.05). However, the subjects were significantly younger in RA than in the OA group (Table 2; 208 
p˂0.0001). There was no significant difference in BMI across groups. 209 
The mean ± 95CI% concentrations of Col10neo in control, OA and RA groups were 2.95 [2.71-3.19] µg/mL, 210 
4.04 [3.84-4.25] μg/mL and 2.55 [2.29-2.81] μg/mL, respectively (Fig. 5A). Plasma Col10neo level was 211 
significantly higher in OA than healthy control (p=0.0002) and RA (p<0.0001). Tests of Between-Subjects 212 
Effects have shown that there was an overall statistically significant difference in Col10neo levels between 213 
different groups when adjusted for covariates (p<0.001). After adjusting for covariates -age, gender, and 214 
BMI, Col10neo level remained significantly higher in the knee OA patients compared to other two groups 215 
(Table 3).  216 
ROC analysis was carried out to evaluate the discriminative power of Col10neo between OA and RA. The 217 
area under the ROC curve (AUC) was 0.875 [0.806-0.943] (P˂0.0001), indicating there is good separation of 218 
Col10neo between the two groups (Fig. 5B). 219 
Discussion 220 
Our current findings suggest that the Cathepsin K-generated neo-epitope of type X collagen,     221 
479
GIATKGLNGP can be detected in blood circulation, where its concentration reflects the hypertrophic 222 
change in phenotype of chondrocytes in articular cartilage and shows good separation of OA from RA. 223 
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Therefore, this neo-epitope can serve as a biomarker for hypertrophic chondrocytes and may have many 224 
potential clinical applications.  225 
Type X collagen is a short and non-fibril forming collagen containing three identical chains.  Type X collagen 226 
is well-recognized as a specific marker for hypertrophic chondrocytes
22
. It is synthesized primarily by 227 
hypertrophic chondrocytes in the growth plate of fetal cartilage and believed to regulate bone   228 
mineralization during endochondral ossification
23
. The evidence for the up-regulation of type X collagen in 229 
osteoarthritic cartilage on mRNA level or protein level by immunohistochemistry has been found in      230 
multiple studies
10,24,22,25,26
.   In the current study, we have observed that type X collagen was stained 231 
pericellularly with antibodies to the neo-epitope or C-terminus of type X collagen and distributed 232 
extracellularly around chondrocyte clusters in the fibrillated superficial layer of osteoarthritic cartilage. This 233 
is consistent with previous studies regarding the deposition of type X collagen by chondrocytes in OA 234 
cartilage
10,22
. Our findings confirm the notion of chondrocyte phenotype modulation in OA that   235 
chondrocytes in diseased cartilage undergo terminal differentiation to hypertrophy. Moreover, some 236 
characteristics of OA such as remodeling of extracellular matrix by proteases, vascularization and focal 237 
calcification of joint resemble the physiological differentiation process of chondrocyte during skeletal 238 
development
4,27,7,12,6
. 239 
The in vitro cleavage of human cartilage suggests that the neo-epitope of type X collagen, 
479
GIATKGLNGP, 240 
was efficiently generated by Cathepsin K among a series of tested proteases. Collagenase is known to be 241 
capable of cleaving type X collagen at least two cleavage sites, G
151
-
152
I and G
479
-
480
I,  within its triple-helical 242 
domain
28,29
. One site is near the amino-terminus of the triple helix, and another site is close to the carboxyl 243 
terminus of the triple helix. As a consequence, these two cleavages generate three products, a 32-kDa 244 
fragment containing the major triple-helix domain, a 9-kDa fragment from the amine-end of type X collagen 245 
and another 18-kDa fragment containing the entire globular domain at the carboxyl end. Interestingly, the 246 
newly identified cleavage site from human OA urine in the current study was verified to be generated by 247 
Cathepsin K. This cleavage site at A
478
-
479
G bond is located an amino acid apart from the proposed  248 
collagenase G
479
-
480
I. Not surprisingly, both bonds are in the same region where the Gly-Ile-Ala triplet was 249 
disrupted by two additional amino acids from the next triplet. Because of the interruption, the region is 250 
inevitably susceptible to attacks by a protease. Furthermore, increased expression and activation of 251 
Cathepsin K has been reported in a transgenic mouse model for osteoarthritis and human osteoarthritic 252 
cartilage
30,31
.  It is still uncertain whether cleavage of collagenases occurs prior to cleavage of Cathepsin K. 253 
Further investigation is required. To sum up, our data suggest that Cathepsin K is potentially involved in the 254 
turnover of type X collagen which is expressed by hypertrophic chondrocytes in OA.  255 
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Most interestingly, a recently published study has shown that a group of fragments containing the entire   256 
C1q domain and variable portions of the attached linker and collagenous region designated as CXM, was a 257 
degradation product of type X collagen during endochondral ossification and an ideal biomarker for the 258 
overall growth plate activity
32
. The serum-based assay for CXM used in this study was built upon a   259 
monoclonal antibody X34 specifically targeting a multimeric form of the NC1 domain, the ~50kDa NC1 260 
region
10
. In the present study, a similar major band of 50 kDa was detected in the Cathepsin K-generated 261 
human cartilage products by 2F4, a mAb specific to the neo-epitope 
479
GIATKGLNGP. It most likely consists 262 
of the compact coiled C1q-like domain which has been reported to resist further proteolysis in other 263 
studies
33,34
. In our previous study, 11G8, an antibody raised against the last 10 amino acids at the carboxyl 264 
end of type X collagen only recognizes the monomeric NC1 domain, ~18kDa 
17
.  Given that the dominant  265 
form of the NC1 domain in circulation is an intact trimer, it is not surprising that Col10neo levels are    266 
generally higher than C-Col10 in the same samples of clinical study C4Pain. 267 
To the best of knowledge, it is the first time that a single biomarker has shown the possibility of   268 
distinguishing OA from RA. Although both arthritis diseases affect joint, the molecular mechanisms of 269 
cartilage breakdown are quite different in OA and RA. The role of terminally differentiated hypertrophic 270 
chondrocytes in OA is still controversial. One study has shown the loss of expression of SOX-9, a 271 
transcription factor inhibiting the differentiation progression of chondrocytes during endochondral 272 
ossification, but a significant down-regulation of type X collagen gene expression in chondrocytes from OA 273 
patients compared to age-matched controls
35
. However, there is increasing evidence to support changes in 274 
the phenotypic state of   chondrocytes in OA. One important study demonstrated that the chemokines 275 
were retained by binding to heparan sulfate proteoglycans to maintain chondrocyte resting phenotype. The 276 
release of chemokines  during cartilage degradation in OA contributes to chondrocyte phenotype shift
36
. 277 
Further damage is caused by proteolytic enzymes secreted by hypertrophic chondrocytes which in return 278 
will lead to more loss of stability of chondrocytes, amplifying a vicious circle. To explain the discrepancy 279 
between studies, there   might be different patient subgroups existing as shown by the scattered Col10neo 280 
levels in the OA group in the current study. The question if chondrocyte hypertrophy differentiation is a 281 
generalized phenomenon in OA needs to be further investigated. RA is a chronic systemic inflammatory 282 
disease instead, which is characterized by synovial lining cell proliferation, inflammatory cell infiltration, 283 
and destruction of cartilage and bone. Therefore, the underlying molecular mechanisms behind the 284 
pathogenesis of OA and RA may be different. We speculate that in OA, the hypertrophy phenotypic 285 
changes in chondrocyte embedded in cartilage play a critical role in the degradation of cartilage matrix. 286 
However, in RA, fibroblast-like   synoviocytes (FLS) are the predominant cell type and contribute to the 287 
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destruction of cartilage
37
. This might explain the findings from the present study that Col10neo, a 288 
degradation biomarker of type X collagen, is significantly higher in OA than RA. 289 
The limitations of this study were: 1) the tissue-specificity of the serological Col10neo level. Although type X 290 
collagen is exclusively expressed by hypertrophic chondrocytes in cartilage, it has been found in human 291 
lumbar intervertebral discs 
38,
 
39
. We previously reported that C-Col10, an assay measuring the C-terminus   292 
of type X collagen, was significantly higher in spondyloarthritis (SpA) patients due to the syndesmophyte 293 
outgrowth similar to osteophyte formation in OA
40
. Thus, the origin of serological Col10neo is worthy of 294 
further investigation. 2) Small sample size study. A study with larger sample size is needed to see if the 295 
findings from this study can be generalized. 3). The unequal sample size in different groups, which might 296 
minimize the statistical power. We noted that it was an exploratory research and cohorts with larger 297 
samples might be useful for validating this biomarker in the future research.  298 
In conclusion, our findings raise the possibility that Col10neo linked to hypertrophic chondrocyte could be 299 
used as a biochemical marker for knee OA with a diagnostic potential in OA and RA, and also help get a 300 
better understanding of the role of hypertrophic chondrocytes in the pathogenesis of OA. 301 
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Figure Legends  
1. Schematic illustration of the positions of neo-epitope, collagenase cleavage site and antibody-binding sites 
on type X collagen. (A)The red line is the location of neo-epitope recognized by 2F4 in the triple helix domain. 
The purple line is the binding site of 11G8 at the C-terminal of NC1 domain. The yellow line is the proposed 
cleavage site by collagenase in other studies. The C1q-like C-terminal NC1 domain forms a stable homotrimer. 
(B)The specificity of 2F4 tested by three synthetic peptides: selection peptide, elongated peptide, and 
truncated peptide, and two truncated recombinant type X collagen proteins: Col10 with free 479Gly (AA 479-
680) and Col10 (AA 450-680), 30aa longer and spanning the cleavage site A
478
-
479
G. 
 
2. in vitro cleavage of cartilage by enzymes. (A) The cleaved human cartilage by MMPs, ADAMTSs, and 
Cathepsins was applied to Col10neo assay. It has been shown that Cathepsin K was the only one among 
tested proteases to release the neo-epitope. The data were shown as mean±SD. (B) Western blot of human 
cartilage cleaved by Cathepsin K. Equivalent blots was probed with antibodies to 2F4 (left panels) or in the 
presence of selection peptide (middle panel) or elongated peptide (right panel) or 11G8 (the fourth panel).  
 
3. Immunolocalization of 479GIATKG in cartilage. (A-C). Histology with Safranin O/Fast green. A. The normal-
arranged chondrocytes, smooth surface and mild degradation of superficial zone proteoglycan in first biopsy 
and  B. less smooth surface and moderate degradation of proteoglycan in the cartilage matrix in the second 
biopsy. C. chondrocyte cluster, fibrillated surface, cleft and severe reduction in safranin O/Fast green was 
found. (D-F) immunostaining with the 
479
GIATKG antibody. G-I immunostaining with C-terminus 11G8.  (J-L) 
with non-sense mouse IgG as negative control. Scale bar in A-C=100µm; Scale bar in D-L=20µm. 
 
4. Association between KL grade and Col10neo level in the plasma of subjects in the C4Pain study. The data 
were shown as mean±95CI%. (A) There was a trend toward a higher level of Col10neo in subjects with greater 
KL score, but do not reach statistical significance. (B) The greatest percent of subjects with KL3-4 was in the 
highest tertile of Col10neo. The one-way ANOVA with post-hoc Tukey-Kramer test was used. Plasma 
Col10neo data were logarithmic transformed in all analyses. A P value<0.05 was considered statistically 
significant.  
 
5. Plasma Col10neo levels in the NYU study. (A)The data were shown as mean±95CI%. Col10neo was 
statistically higher in OA than control (p=0.0002) or RA (p<0.0001), and no significant difference was seen 
between control and RA. The one-way ANOVA with post-hoc Tukey-Kramer test was used. Plasma Col10neo 
were logarithmic transformed in all analyses. P value<0.05 was considered statistically significant. (B) ROC 
curve analysis. The area under the ROC curve (AUC) was 0.875 (95% confidence interval 0.806-0.9427; 
P˂0.0001), indicating there was a good separation of Col10neo of two groups 
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Table 1. Demographics of subjects in the C4Pain study 
KL grade No. of women  No. Of men Total VAS grade Age, years BMI, kg/m2 
0-1 23 27 50 37±30 61.8±8.5 26.4±3.1 
2 79 66 145 42±29 64.6±7.3 28.2±3.8 
3 17 19 36 56±21 64.3±7.1 29.3±5.6 
4 12 10 22 54±24 67.8±7.7$ 29.5±3.9 
Except where indicated otherwise, values are the mean ± SD. Vas grade=maximal pain intensity for the last  
24 hour, BMI = body mass index. 
$, P<0.05 compared to KL0-1 group  
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Table 2. Demographics of subjects in the NYU study  
  Non-OA Controls OA  RA  
No. of men 12 56 6 
No. of women 8 86 28 
Total No. 20 142 34 
Age, years 56.7±8.7# 62.5±10.1 53.2±10.5$$$$ 
BMI, kg/m2 26.75±4.14 26.58±3.62 27.99±5.70 
KL score ≤1 KL 0-4  Not Available 
Treatments No 21.8 percent of the 142 enrolled 
OA patients were taking NSAIDs. 
All enrolled 34 RA patients 
were taking vitamin or mineral 
supplements or medication 
treating high blood pressure. 
Besides, 34 percent were 
taking biologics (such as 
Orenica, Humira, and Enbrel); 
71 percent were on 
methotrexate and among 
methotrexate patients 48 
percent were on biologics. 
 
Except where indicated otherwise, values are the mean ± SD. BMI = body mass index. 
#, p<0.05 compared to OA group 
$$$$, p<0.0001 compared to OA group 
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Table. 3 ANCOVA analysis of plasma Col10neo levels adjusted for age, gender, and BMI. 
Factors Mean difference Std. Error P 
a
 95% CI a 
OA - Non-OA 
control 
0.1152 0.02926 0.0003 0.04453 to 0.1866 
  - RA 0.2176 0.02477 <0.0001 0.1578to 0.2774 
Non-OA 
control 
- OA -0.1152 0.02926 0.0003 -0.1859 to -0.04453 
 - RA 0.1024 0.03487 0.0112 0.01819to 0.04453 
  a Bonferroni corrected 
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Fig. 5  
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